The aim of this review is to investigate the detection rate of PSMA-PET compared to other radiopharmaceuticals (especially [18F]FDG) in non-prostatic tumors in order to identify patients with solid tumors who may benefit from this theragnostic agent. The gene discussed is FOLH1; the disease is prostate neoplasm.